1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
Chemotherapy dosing during pregnancy Are there any guidelines for chemotherapy dose modifications during pregnancy based on the increasing maternal body weight, or would the initial body weight be used for the BSA calculation throughout the pregnancy? If the dose is adjusted, would this be done prior to each cycle? I look forward to hearing your opinion. Kind regards, Sabine Kaestner MPharmSci, PhD (UK)
Pregnancy, in addition to increased body weight, is associated with increased metabolism due to heightened activity of several cytochrome enzymes, including CYP3A4 and CYP2A6. Presently, no study has evaluated pharmacokinetic changes of chemotherapeutic agents during pregnancy and no guidelines for dose adjustment exist.
Because most of the changes in body weight occur late in pregnancy, it is conceivable to consider changes in dose if there is evidence of decreased pharmacological response to the drug. This must be done case-by-case by the team, considering efficacy, toxicity and fetal well-being.